October 13, 2016
Grifols relocates its headquarters in Germany to a new office building
Grifols has a commercial subsidiary in Germany since 1997 and following the acquisition of Talecris in 2011, the country also hosts the commercial headquarters of the Bioscience Division in Europe
- Grifols has a commercial subsidiary in Germany since 1997 and following the acquisition of Talecris in 2011, the country also hosts the commercial headquarters of the Bioscience Division in Europe
- The new office building in Frankfurt will allow Grifols to consolidate its presence in Germany at a single location
Frankfurt, October 13, 2016 – Grifols (MCE: GRF, MCE: GRF.P and NASDAQ: GRFS), a global healthcare company with more than 75-year legacy of improving people's health and well-being through the development of protein therapies, hospital pharmacy products and diagnostic technology for clinical use, has relocated its headquarters in Germany to a new office building, evidencing its commitment to Frankfurt.
The new Grifols building located in Frankfurt, also home to the previous offices, has approximately 5,400 square meters distributed over five floors and hosts the Sales and Marketing of Grifols Germany. The logistic function, currently managed from Langen, will also move to the new building in December, where they will have a warehouse of over 1,500 square meters dedicated to the distribution of Grifols' products nationwide.
For Ainhoa Mendizabal, Managing Director of Grifols Germany: "the new Grifols building has been built according to our needs to support our growth strategy in Germany.In addition, it allows all Grifols Germany employees to work at a single location". The Managing Director also highlights that "the location, with its proximity tothe International Airport of Frankfurt and highways, is exceptional".